Skip to main content

Table 2 Baseline prevalence rates for Taiwanese adult workers not fulfilling metabolic syndrome (MetS) criteria initially

From: Worksite health screening programs for predicting the development of Metabolic Syndrome in middle-aged employees: a five-year follow-up study

   2002 baseline data, divided by MetS outcome in 2007**  
Abnormality Prevalence* Overall N = 1384 Without MetS outcome n = 1209 With MetS outcome, n = 175 P
MetS component (not segregated)     
   COB 54 (3.9%) 28 (2.3%) 26(14.9%) <0.01
   Hyper-GL 284 (20.5%) 234 (19.4%) 50(28.6%) 0.01
   HBP 245 (17.7%) 193 (16.0%) 52(29.7%) <0.01
   Low-HDL 338 (24.4%) 269 (22.2%) 69(39.4%) <0.01
   Hyper-TG 190 (13.7%) 139 (11.5%) 51(29.1%) <0.01
MetS component (segregated by count and combination)     
   Single component 511 (36.9%) 451 (37.3%) 60 (34.3%) 0.44
Hyper-GL alone 149 (10.8%) 132 (10.9%) 17(9.7%) 0.62
Low-HDL alone 168 (12.1%) 151 (12.5%) 17(9.7%) 0.27
HBP alone 115 (8.3%) 107 (8.9%) 8(4.6%) 0.02
Hyper-TG alone 63 (4.6%) 51 (4.2%) 12(6.9%) 0.19
COB alone 16 (1.2%) 10 (0.8%) 6(3.4%) 0.07
   Two components 300 (21.7%) 206 (17.0%) 94 (53.7%) <0.01
Low-HDL-plus-Hyper-TG 61 (4.4%) 43 (3.6%) 18(10.3%) <0.01
Hyper-GL-plus-Low-HDL 51 (3.7%) 42 (3.5%) 9(5.1%) 0.34
Low-HDL-plus-HBP 42 (3.0%) 26 (2.2%) 16(9.1%) <0.01
Hyper-TG-plus-HBP 31 (2.2%) 22 (1.8%) 9(5.1%) 0.05
Hyper-GL-plus-Hyper-TG 30 (2.2%) 22 (1.8%) 8(4.6%) 0.09
COB-plus-Low-HDL 16 (1.2%) 7 (0.6%) 9(5.1%) <0.01
COB-plus-HBP 10 (0.7%) 5 (0.4%) 5(2.9%) 0.06
COB-plus-Hyper-GL 7 (0.5%) 5 (0.4%) 2(1.1%) 0.38
COB-plus-Hyper-TG 5 (0.4%) 1 (0.1%) 4(2.3%) 0.05
  1. * The abnormality prevalence is demonstrated as numbers and proportions, %. The upper rows are non-segregated distributions of MetS components, one or two risk factors are included and overlapping can happen; the lower rows are segregated by each signal and combinations, all individual conditions are listed. Abbreviations: Hyper-GL, hyperglycemia; Low-HDL, Low-HDL cholesterolemia; HBP, high blood pressure; Hyper-TG, hypertriglyceridemia; COB, central obesity.
  2. **χ2 tests were conducted for categorical variables between groups with/without MetS outcome.
\